Lucid Diagnostics Inc. (LUCD) Stock Ticker
LUCD right now
Market factors today
Unlock the full LUCD picture
About Lucid Diagnostics Inc.
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
LUCD stock facts
| Ticker symbol | LUCD |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Medical - Devices |
| Market cap | $157.6M |
| CEO | Lishan Aklog |
| Employees | 82 |
| Headquarters | New York City, NY, US |
| IPO date | 2021-10-14 |
| Website | www.luciddx.com |
What you can see for LUCD on Tickr
Live LUCD price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the LUCD report.
Rankings
FAQ
What is the ticker symbol for Lucid Diagnostics Inc.?
The ticker symbol for Lucid Diagnostics Inc. is LUCD, listed on the NASDAQ Global Market.
What is LUCD?
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal…